Physician profile
Natasha Lea Smith
NPI 1881233500
$7,322.52
in general payments reported to CMS, 2019-2025
23 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $888 · 2022: $1,084 · 2023: $1,464 · 2024: $2,090 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,827 · Consulting Fee: $276 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,826.76 |
| Consulting Fee | $276.00 |
| Education | $247.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,177.50 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,063.63 | 2021-2025 | |
| Janssen Biotech, INC. | $1,049.17 | 2021-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $807.57 | 2021-2025 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $717.99 | 2021-2025 | Orencia |
| Pfizer INC. | $534.43 | 2021-2025 | |
| Amgen INC. | $507.77 | 2021-2025 | Enbrel, Otezla, Prolia |
| Astrazeneca Pharmaceuticals LP | $425.40 | 2022-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.83 | 2023-2025 | Cyltezo, Ofev |
| Glaxosmithkline, LLC. | $178.55 | 2021-2023 | Benlysta |
| Sobi, INC | $167.99 | 2023-2025 | |
| Sandoz INC. | $75.80 | 2023-2024 | Hyrimoz |
| Genzyme Corporation | $75.23 | 2023-2024 | |
| Lilly USA, LLC | $53.72 | 2024 | Taltz |
| Janssen Scientific Affairs, LLC | $48.77 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $46.05 | 2024-2025 | Ultomiris, Strensiq |
| Mallinckrodt Hospital Products INC. | $34.72 | 2025 | Acthar |
| Radius Health, INC. | $29.66 | 2023-2024 | Tymlos |
| Almatica Pharma LLC | $19.15 | 2024 | Teriparatide |
| Mindera Corp | $18.77 | 2025 | |
| Paratek Pharmaceuticals, INC. | $18.61 | 2023 | Nuzyra |
| Fresenius Kabi USA, LLC | $16.92 | 2023 | Idacio |
| Horizon Therapeutics Plc | $16.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.